Quintiles Transitional Holdings Inc. (Q) Given “Hold” Rating at Jefferies Group LLC
Quintiles Transitional Holdings Inc. (NYSE:Q)‘s stock had its “hold” rating reaffirmed by research analysts at Jefferies Group LLC in a research report issued on Friday. They currently have a $94.00 target price on the medical research company’s stock. Jefferies Group LLC’s target price would indicate a potential upside of 3.96% from the stock’s previous close.
Q has been the topic of several other research reports. Barclays PLC upped their target price on Quintiles Transitional Holdings from $98.00 to $100.00 and gave the stock an “overweight” rating in a report on Friday. Zacks Investment Research lowered Quintiles Transitional Holdings from a “buy” rating to a “hold” rating in a report on Tuesday. William Blair upgraded Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $70.10 to $93.42 in a report on Friday. Evercore ISI reiterated an “in-line” rating and set a $88.50 target price (up previously from $84.00) on shares of Quintiles Transitional Holdings in a report on Thursday, May 4th. Finally, Mizuho upped their target price on Quintiles Transitional Holdings from $90.00 to $93.00 and gave the stock a “buy” rating in a report on Thursday, May 4th. Eleven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $89.41.
Quintiles Transitional Holdings (NYSE:Q) opened at 90.42 on Friday. The stock’s 50 day moving average price is $89.50 and its 200-day moving average price is $82.85. The firm has a market cap of $19.90 billion, a price-to-earnings ratio of 200.04 and a beta of 0.64. Quintiles Transitional Holdings has a one year low of $70.10 and a one year high of $93.53.
Quintiles Transitional Holdings (NYSE:Q) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.04. The company had revenue of $1.97 billion for the quarter, compared to analyst estimates of $1.96 billion. Quintiles Transitional Holdings had a return on equity of 15.68% and a net margin of 0.82%. The company’s quarterly revenue was up 68.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.93 earnings per share. Analysts forecast that Quintiles Transitional Holdings will post $4.55 earnings per share for the current year.
Quintiles Transitional Holdings declared that its board has approved a stock repurchase plan on Wednesday, May 24th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 5.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its shares are undervalued.
In other news, Director Jack M. Greenberg sold 6,092 shares of the company’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $82.50, for a total value of $502,590.00. Following the transaction, the director now owns 2,930 shares of the company’s stock, valued at $241,725. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John G. Danhakl sold 761,143 shares of the company’s stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $84.01, for a total value of $63,943,623.43. The disclosure for this sale can be found here. Insiders sold 8,758,400 shares of company stock worth $735,783,985 in the last ninety days. 6.40% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of Q. Korea Investment CORP increased its position in Quintiles Transitional Holdings by 142.5% in the second quarter. Korea Investment CORP now owns 1,370 shares of the medical research company’s stock valued at $123,000 after buying an additional 805 shares during the last quarter. Global X Management Co. LLC increased its position in Quintiles Transitional Holdings by 30.8% in the first quarter. Global X Management Co. LLC now owns 1,469 shares of the medical research company’s stock valued at $118,000 after buying an additional 346 shares during the last quarter. IFP Advisors Inc increased its position in Quintiles Transitional Holdings by 187.1% in the first quarter. IFP Advisors Inc now owns 1,774 shares of the medical research company’s stock valued at $143,000 after buying an additional 1,156 shares during the last quarter. Archford Capital Strategies LLC purchased a new position in Quintiles Transitional Holdings during the first quarter valued at approximately $160,000. Finally, Bbva Compass Bancshares Inc. purchased a new position in Quintiles Transitional Holdings during the first quarter valued at approximately $170,000. 92.47% of the stock is currently owned by institutional investors.
Quintiles Transitional Holdings Company Profile
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.